Quick Overview
- CMND-100 successfully achieved its primary endpoint during Phase I/IIa clinical testing for Alcohol Use Disorder
- Safety data from the third cohort demonstrated excellent tolerability with zero serious adverse events across all dosage levels
- Shares of CMND climbed more than 100%, reaching approximately $1.44 following the announcement
- This multinational study received FDA approval to assess safety, tolerability, and preliminary efficacy in patients with moderate to severe AUD
- Following comprehensive safety data review, the Data and Safety Monitoring Board greenlit trial continuation
Clearmind Medicine (CMND) experienced dramatic gains on Monday, with shares climbing over 100% after the biopharmaceutical company revealed positive results from its lead compound, CMND-100, in an FDA-authorized Phase I/IIa clinical trial targeting Alcohol Use Disorder.
At publication time, shares were changing hands near $1.44, representing approximately 100% gains during the trading session.
Data from the trial’s third cohort revealed robust safety and tolerability outcomes across all tested dosage levels, including the highest concentrations administered. The study recorded zero serious adverse events.
According to company statements, these findings aligned with observations from previous cohorts, indicating consistent safety characteristics as dosing escalates.
CMND-100 represents a non-hallucinogenic, MEAI-based oral therapeutic candidate currently under development for treating moderate to severe Alcohol Use Disorder.
The ongoing Phase I/IIa investigation operates as a multinational, multicenter study with objectives encompassing safety assessment, tolerability measurement, pharmacokinetic evaluation, and preliminary efficacy indicators.
Significant Milestone Achieved
Successfully reaching the primary endpoint during dose-escalation represents meaningful progress for the development program. Clearmind emphasized that these outcomes bolster the potential of CMND-100 as a viable therapeutic intervention.
Following thorough examination of safety information, the company’s Data and Safety Monitoring Board authorized ongoing trial activities. The study has now enrolled and completed treatment and follow-up protocols for 18 participants.
Clearmind’s research strategy centers on neuroplastogen-derived therapeutic compounds that avoid the hallucinogenic properties linked to certain psychedelic-based interventions.
Company Financial Position
Prior to Monday’s rally, shares had declined approximately 50% during the preceding week. The stock was valued at merely $0.72 with total market capitalization hovering around $1.5 million.
The organization maintains a favorable balance sheet with cash reserves exceeding debt obligations and liquid assets surpassing near-term liabilities. This financial positioning provides operational capacity as clinical development progresses.
Clearmind’s intellectual property holdings encompass 19 patent families alongside 31 granted patents. The company recently submitted a patent application to the Indian Patent Office covering psychedelic-based compounds for mental health and addiction therapy applications.
This patent filing connects to a licensing arrangement with Yissum Research Development Company, which handles commercialization activities for the Hebrew University of Jerusalem.
CMND was trading at $1.44, up 100.06%, at time of publication, according to Benzinga Pro data.
